Miyamoto Tomoyuki, Numahata Kyoko, Ishido Hideaki, Miyamoto Masayuki
Department of Neurology, Dokkyo Medical University Saitama Medical Center.
Brain Nerve. 2020 Feb;72(2):107-117. doi: 10.11477/mf.1416201490.
REM sleep behavior disorder (RBD) can progress to Parkinson's disease, Lewy body dementia, or multiple system atrophy within 20 years of onset. Accurate diagnosis of RBD is therefore important for early intervention. The development of markers that can more sensitively evaluate the effects of high-risk groups or candidate therapies that develop α-synucleinopathy in the short term is the key to a successful clinical trial. Clinical protocols for early diagnosis of α-synucleinopathy are currently being developed. The next stage will be to conduct clinical trials for candidate therapies.
快速眼动睡眠行为障碍（RBD）在发病20年内可能会进展为帕金森病、路易体痴呆或多系统萎缩。因此，准确诊断RBD对于早期干预很重要。开发能够更敏感地评估高危人群的影响或在短期内发展为α-突触核蛋白病的候选疗法的标志物是成功开展临床试验的关键。目前正在制定α-突触核蛋白病早期诊断的临床方案。下一阶段将是对候选疗法进行临床试验。
